Valproate attenuates 25-kDa C-terminal fragment of TDP-43-induced neuronal toxicity via suppressing endoplasmic reticulum stress and activating autophagy

International Journal of Biological Sciences

Volumn 11, Issue 7, 2015, Pages 752-761

  Wang, Xuejing ^a   Ma, Mingming ^b   Teng, Junfang ^a   Che, Xiangqian ^d   Zhang, Wenwen ^a   Feng, Shuman ^b   Zhou, Shuang ^c   Zhang, Ying ^c   Wu, Erxi ^c   Ding, Xuebing ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c NORTH DAKOTA STATE UNIVERSITY   (United States)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

25 kDa C terminal fragment of TDP 43; Amyotrophic lateral sclerosis; Autophagy; Endoplasmic reticulum stress; Valproate

Indexed keywords

DNA BINDING PROTEIN; PEPTIDE FRAGMENT; TDP-43 PROTEIN, MOUSE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; VALPROIC ACID;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL; AUTOPHAGY; CELL LINE; DRUG EFFECTS; ENDOPLASMIC RETICULUM STRESS; FLOW CYTOMETRY; GENETICS; IMMUNOBLOTTING; METABOLISM; MOUSE; NERVE CELL;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; AUTOPHAGY; CELL LINE; DNA-BINDING PROTEINS; ENDOPLASMIC RETICULUM STRESS; FLOW CYTOMETRY; IMMUNOBLOTTING; MICE; NEURONS; PEPTIDE FRAGMENTS; TETRAZOLIUM SALTS; THIAZOLES; VALPROIC ACID;

EID: 84933511936     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.11880     Document Type: Article

References (51)

1. Bakkar N, Boehringer A, Bowser R. Use of biomarkers in ALS drug development and clinical trials. Brain Res. 2014.
2. Malaspina A, Puentes F, Amor S. Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective. Int Immunol. 2014.
3. de Carvalho M, Eisen A, Krieger C, Swash M. Motoneuron firing in amyotrophic lateral sclerosis (ALS). Front Hum Neurosci. 2014; 8: 719.
4. Kim C, Lee HC, Sung JJ. Amyotrophic lateral sclerosis - cell based therapy and novel therapeutic development. Exp Neurobiol. 2014; 23: 207-14.
5. Chen S, Zhang X, Song L, Le W. Autophagy dysregulation in amyotrophic lateral sclerosis. Brain Pathol. 2012; 22: 110-6.
6. Walker AK, Soo KY, Sundaramoorthy V, Parakh S, Ma Y, Farg MA, et al. ALS-associated TDP-43 induces endoplasmic reticulum stress, which drives cytoplasmic TDP-43 accumulation and stress granule formation. PLoS One. 2013; 8: e81170.
7. Consilvio C, Vincent AM, Feldman EL. Neuroinflammation, COX-2, and ALS--a dual role? Exp Neurobiol. 2004; 187: 1-10.
8. Ruble BK, Richards JL, Cheung-Lau JC, Dmochowski IJ. Mismatch Discrimination and Efficient Photomodulation with Split 10-23 DNAzymes. Inorganica chimica acta. 2012; 380: 386-91.
9. Pollari E, Goldsteins G, Bart G, Koistinaho J, Giniatullin R. The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis. Front Cell Neurosci. 2014; 8: 131.
10. Sreedharan J, Brown RH, Jr. Amyotrophic lateral sclerosis: Problems and prospects. Ann Neurol. 2013; 74: 309-16.
11. Poppe L, Rue L, Robberecht W, Van Den Bosch L. Translating biological findings into new treatment strategies for amyotrophic lateral sclerosis (ALS). Exp Neurobiol. 2014; 262(Pt B): 138-51.
12. Yang C, Tan W, Whittle C, Qiu L, Cao L, Akbarian S, et al. The C-terminal TDP-43 fragments have a high aggregation propensity and harm neurons by a dominant-negative mechanism. PLoS One. 2010; 5: e15878.
13. Forman MS, Trojanowski JQ, Lee VM. TDP-43: a novel neurodegenerative proteinopathy. Curr Opin Neurobiol. 2007; 17: 548-55.
14. Suzuki H, Lee K, Matsuoka M. TDP-43-induced death is associated with altered regulation of BIM and Bcl-xL and attenuated by caspase-mediated TDP-43 cleavage. J Biol Chem. 2011; 286: 13171-83.
15. Lagier-Tourenne C, Cleveland DW. Rethinking ALS: the FUS about TDP-43. Cell. 2009; 136: 1001-4.
16. Liscic RM, Grinberg LT, Zidar J, Gitcho MA, Cairns NJ. ALS and FTLD: two faces of TDP-43 proteinopathy. Eur J Neurol. 2008; 15: 772-80.
17. Budini M, Buratti E, Stuani C, Guarnaccia C, Romano V, De Conti L, et al. Cellular model of TAR DNA-binding protein 43 (TDP-43) aggregation based on its C-terminal Gln/Asn-rich region. J Biol Chem. 2012; 287: 7512-25.
18. Hong K, Li Y, Duan W, Guo Y, Jiang H, Li W, et al. Full-length TDP-43 and its C-terminal fragments activate mitophagy in NSC34 cell line. Neurosci Lett. 2012; 530: 144-9.
19. Dayton RD, Gitcho MA, Orchard EA, Wilson JD, Wang DB, Cain CD, et al. Selective forelimb impairment in rats expressing a pathological TDP-43 25 kDa C-terminal fragment to mimic amyotrophic lateral sclerosis. Mol Ther. 2013; 21: 1324-34.
20. Cincarova L, Zdrahal Z, Fajkus J. New perspectives of valproic acid in clinical practice. Expert Opin Investig Drugs. 2013; 22: 1535-47.
21. Wang W, Liao XL, Chen JH, Li DD, Lin CL, Yan YX, et al. Sodium valproate induces mitochondria-dependent apoptosis in human hepatoblastoma cells. Chin Med J (Engl). 2011; 124: 2167-72.
22. Rouaux C, Panteleeva I, Rene F, Gonzalez de Aguilar JL, Echaniz-Laguna A, Dupuis L, et al. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J Neurosci. 2007; 27: 5535-45.
23. Tremolizzo L, Rodriguez-Menendez V, Sala G, Di Francesco JC, Ferrarese C. Valproate and HDAC inhibition: a new epigenetic strategy to mitigate phenotypic severity in ALS? Amyotroph Lateral Scler Other Motor Neuron Disord. 2005; 6: 185-6.
24. Sugai F, Yamamoto Y, Miyaguchi K, Zhou Z, Sumi H, Hamasaki T, et al. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur J Neurosci. 2004; 20: 3179-83.
25. Huang S, Zhu M, Wu W, Rashid A, Liang Y, Hou L, et al. Valproate pretreatment protects pancreatic beta-cells from palmitate-induced ER stress and apoptosis by inhibiting glycogen synthase kinase-3beta. J Biomed Sci. 2014; 21: 38.
26. Khan S, Jena G, Tikoo K, Kumar V. Valproate attenuates the proteinuria, podocyte and renal injury by facilitating autophagy and inactivation of NF-kappaB/iNOS signaling in diabetic rat. Biochimie. 2015.
27. Chiu CT, Wang Z, Hunsberger JG, Chuang DM. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev. 2013; 65: 105-42.
28. Tremolizzo L, Sala G, Conti E, Rodriguez-Menendez V, Fogli A, Michelucci A, et al. Valproate Treatment in an ALS Patient Carrying a c.194G>A Spastin Mutation and SMN2 Homozygous Deletion. Case Rep Neurol Med. 2014; 2014: 216094.
29. Boll MC, Bayliss L, Vargas-Canas S, Burgos J, Montes S, Penaloza-Solano G, et al. Clinical and biological changes under treatment with lithium carbonate and valproic acid in sporadic amyotrophic lateral sclerosis. J Neurol Sci. 2014; 340: 103-8.
30. Crochemore C, Virgili M, Bonamassa B, Canistro D, Pena-Altamira E, Paolini M, et al. Long-term dietary administration of valproic acid does not affect, while retinoic acid decreases, the lifespan of G93A mice, a model for amyotrophic lateral sclerosis. Muscle Nerve. 2009; 39: 548-52.
31. Feng HL, Leng Y, Ma CH, Zhang J, Ren M, Chuang DM. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience. 2008; 155: 567-72.
32. Piepers S, Veldink JH, de Jong SW, van der Tweel I, van der Pol WL, Uijtendaal EV, et al. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol. 2009; 66: 227-34.
33. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65: 55-63.
34. Wang X, Fan H, Ying Z, Li B, Wang H, Wang G. Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system. Neurosci Lett. 2010; 469: 112-6.
35. Lautenschlaeger J, Prell T, Grosskreutz J. Endoplasmic reticulum stress and the ER mitochondrial calcium cycle in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012; 13: 166-77.
36. Mutihac R, Alegre-Abarrategui J, Gordon D, Farrimond L, Yamasaki-Mann M, Talbot K, et al. TARDBP pathogenic mutations increase cytoplasmic translocation of TDP-43 and cause reduction of endoplasmic reticulum Ca signaling in motor neurons. Neurobiol Dis. 2014; 75C: 64-77.
37. Song CY, Guo JF, Liu Y, Tang BS. Autophagy and Its Comprehensive Impact on ALS. Int J Neurosci. 2012; 122: 695-703.
38. Liu Y, Duan W, Guo Y, Li Z, Han H, Zhang S, et al. A new cellular model of pathological TDP-43: The neurotoxicity of stably expressed CTF25 of TDP-43 depends on the proteasome. Neuroscience. 2014; 281C: 88-98.
39. Wang IF, Guo BS, Liu YC, Wu CC, Yang CH, Tsai KJ, et al. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc Natl Acad Sci U S A. 2012; 109: 15024-9.
40. Igaz LM, Kwong LK, Chen-Plotkin A, Winton MJ, Unger TL, Xu Y, et al. Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies. J Biol Chem. 2009; 284: 8516-24.
41. Ugras SE, Shorter J. RNA-Binding Proteins in Amyotrophic Lateral Sclerosis and Neurodegeneration. Neurol Res Int. 2012; 2012: 432780.
42. King OD, Gitler AD, Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 2012; 1462: 61-80.
43. Rao RV, Bredesen DE. Misfolded proteins, endoplasmic reticulum stress and neurodegeneration. Curr Opin Cell Biol. 2004; 16: 653-62.
44. Ilieva EV, Ayala V, Jove M, Dalfo E, Cacabelos D, Povedano M, et al. Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain. 2007; 130: 3111-23.
45. Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature. 2006; 441: 885-9.
46. Garcia-Arencibia M, Hochfeld WE, Toh PP, Rubinsztein DC. Autophagy, a guardian against neurodegeneration. Semin Cell Dev Biol. 2010; 21: 691-8.
47. Bown CD, Wang JF, Chen B, Young LT. Regulation of ER stress proteins by valproate: therapeutic implications. Bipolar Disord. 2002; 4: 145-51.
48. Penas C, Verdu E, Asensio-Pinilla E, Guzman-Lenis MS, Herrando-Grabulosa M, Navarro X, et al. Valproate reduces CHOP levels and preserves oligodendrocytes and axons after spinal cord injury. Neuroscience. 2011; 178: 33-44.
49. Cheung ZH, Ip NY. Autophagy deregulation in neurodegenerative diseases recent advances and future perspectives. J Neurochem. 2011; 118: 317-25.
50. Barmada SJ, Serio A, Arjun A, Bilican B, Daub A, Ando DM, et al. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat Chem Biol. 2014; 10: 677-85.
51. Fu J, Shao CJ, Chen FR, Ng HK, Chen ZP. Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro Oncol. 2010; 12: 328-40.